Get started
Author

Silvia Ling

Observed names: S C W Ling, S Ling, S. C. W. Ling, S. Ling, Silvia C W Ling, Silvia C. Ling, Silvia C. W. Ling, Silvia C.W. Ling, Silvia CW Ling
Observed institutions: Sydney Adventist Hospital, Royal Prince Alfred Hospital, Centenary Institute, Liverpool Hospital, UNSW Sydney, Ingham Institute, First Affiliated Hospital Zhejiang University, NSW Health Pathology, Western Sydney University, Zhejiang University
ORCID: 0000-0001-9739-7101
Observed ORCID: 0000-0001-9739-7101
OpenAlex ID: A5006060652
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1
2011 · S. C. W. Ling, E. K. K. Lau, et al. · Haematologica · 130
PDF
Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance
2018 · Nicholas Nikesitch, James M Lee, et al. · Clinical & Translational Immunology · 107
PDF
Molecular mechanisms in multiple myeloma drug resistance
2015 · Nicholas Nikesitch, Silvia C W Ling · Journal of Clinical Pathology · 84
PDF
Bisphosphonate guidelines for treatment and prevention of myeloma bone disease
2017 · Oi Lin Lee, Noemi Horvath, et al. · Internal Medicine Journal · 29
PDF
Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response
2016 · N Nikesitch, C Tao, et al. · Blood Cancer Journal · 28
PDF
The prognostic value of mid- and post-treatment [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma
2014 · Zhou Lu, Michael Lin, et al. · Annals of Nuclear Medicine · 28
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
2025 · Sikander Ailawadhi, Ivan Špička, et al. · Journal of Clinical Oncology · 22
Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs
2025 · Julie A. I. Thoms, Feng Yan, et al. · Nature Communications · 21
PDF
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia
2023 · Shirlene Sim, Anna Kalff, et al. · Internal Medicine Journal · 19
The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma
2021 · Nicholas Nikesitch, Patricia Rebeiro, et al. · Cells · 19
PDF
Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?
2006 · Silvia Ling, Douglas E. Joshua, et al. · American Journal of Hematology · 18
Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis.
2024 · Nizar J. Bahlis, Rakesh Popat, et al. · Journal of Clinical Oncology · 14
Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA
2023 · Royston Ponraj, Adam Bryant, et al. · Blood Cancer Journal · 9
PDF
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study
2025 · Rakesh Popat, Meral Beksac, et al. · Journal of Clinical Oncology · 6
PDF
Intravenous immunoglobulin induces short‐term reversal of drug‐induced autoimmune neutropenia
2015 · B. Getta, G. Ponniah, et al. · Transfusion Medicine · 6
The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma
2023 · A-M Joëlle Marivel, Yafeng Ma, et al. · Leukemia Research Reports · 3
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group
2022 · Dipti Talaulikar, Douglas Joshua, et al. · Internal Medicine Journal · 3
PDF
The prognostic value of 18-FDG positron emission tomography in T cell non-Hodgkin lymphoma
2017 · R Eslick, L Dunlop, et al. · Blood Cancer Journal · 3
PDF
Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres
2020 · Georgia J. McCaughan, Anvita Verma, et al. · Bone Marrow Transplantation · 2
Characterization of Bortezomib Resistance in Multiple Myeloma Cell Lines
2008 · Silvia CW Ling, Angela M Nikolic, et al. · Blood · 2
Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma
2026 · Enrique M. Ocio, Gurdeep Parmar, et al. · Expert Opinion on Drug Delivery · 1
Isatuximab Subcutaneous via an on-body Delivery System versus Isatuximab Intravenous, Plus Pomalidomide and Dexamethasone, in Relapsed/Refractory Multiple Myeloma: The Randomized Phase 3 IRAKLIA Study
2025 · Sikander Ailawadhi, Ivan Špička, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
2025 · Sikander Ailawadhi, Ivan Špička, et al. · Journal of Clinical Oncology · 1
Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.
2025 · Sikander Ailawadhi, Ivan Spicka, et al. · Journal of Clinical Oncology · 1
PDF
A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies
2024 · Eric Wenlong Li, Esther Jones, et al. · European Journal Of Haematology · 1
PDF
Works count: 63
Citation count: 561
H-index: 12
I10-index: 12
Year
Topic
Type